Evidence map›Paper›PMID 28009326›Full record

ArticleCancer biomarkers : section A of Disease markers2017

ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes.

Anna Caliò, Emilio Bria, Sara Pilotto, Eliana Gilioli, Alessia Nottegar, Albino Eccher, Luca Cima, Antonio Santo, Serena Pedron, Giona Turri and 10 more

Open access · greenAbstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 4 countries.

Anna CaliòDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
Emilio BriaMedical Oncology, University and Hospital Trust, Verona, Italy.
Sara PilottoMedical Oncology, University and Hospital Trust, Verona, Italy.
Eliana GilioliDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
Alessia NottegarDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
Albino EccherDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
Luca CimaDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
Antonio SantoMedical Oncology, University and Hospital Trust, Verona, Italy.
Serena PedronDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
Giona TurriDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
Sakari KnuutilaDepartment of Pathology, Laboratory of Molecular Cytogenetic, University of Helsinki, Helsinki, Finland.
Marco ChilosiDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
Francesca VanzoArsenàl, Veneto's Research Center for eHealth Innovation, Veneto, Italy.
Giuseppe BoginaAnatomic Pathology, SacroCuore Hospital, Negrar, Italy.
Alberto TerziThoracic Surgery, SacroCuore Hospital, Negrar, Italy.
Giampaolo TortoraMedical Oncology, University and Hospital Trust, Verona, Italy.
Aldo ScarpaDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
Massimo LodaDana-Farber Cancer Institute, Harvard Medical School, Brigham And Women's Hospital, Boston, MA, USA.
Guido MartignoniDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
Matteo BrunelliDepartment of Diagnostics and Public Health, Anatomic Pathology, University and Hospital Trust, Verona, Italy.
University Hospital Foundation · CAOspedale Sacro Cuore Don Calabria · ITCasa di Cura Villa Garda · ITDana-Farber Brigham Cancer Center · USRegione del Veneto · ITUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGains of a gene due to DNA polyploidy versus amplification of the specific locus are distinct molecular alterations in tumors.

objectiveWe quantified copy number gains of ALK gene due to unspecific polyploidy versus amplifications of the specific locus in a series of non-small cell lung cancers.

methodsThe locus specific ALK copy (LSI) number status was evaluated in 205 cases by FISH. Ratio LSI ALK copy number corrected for control probes CEP2, CEP3 and CEP17 (CEPs) was scored. Amplification of the specific ALK locus was defined when ratio set to ≥ 2 while polyploidy was interpreted when the increase in gene copy resulted < 2 in ratio (LSI/control CEPs).

resultsTwenty one cases (10.2%) showed ≥ 8 ALK signals, 68 cases (33.2%) 3-7 signals and 116 cases (56.6%) a mean of 2 signals. Only 2/21 cases of the cohort harboring ≥ 8 signals showed a ratio ≥ 2 after CEPs correction interpretable as amplified, showing numerous doubled fluorescent spots. All the remaining cases showed a mirrored number of fluorescent spots per each CEPs, interpretable as polyploidy.

conclusionWe detected a high prevalence of ALK gene copy number usually due to polyploidy rather than ALK locus amplification, the latter visible prevalently as double minutes.

Indexed as

Gene DosageAdenocarcinomaAdenocarcinoma of LungAnaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungErbB ReceptorsGene AmplificationHumansIn Situ Hybridization, FluorescenceLung NeoplasmsMutationNeoplasms, Squamous CellPolyploidyReceptor Protein-Tyrosine KinasesALK protein, humanAnaplastic Lymphoma KinaseEGFR protein, humanErbB ReceptorsReceptor Protein-Tyrosine KinasesALK gene copy numberamplificationdouble minutesgainspolyploidy

Identifiers

PMID28009326
PMCPMC13020586
OpenAlexW2562879586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.